LAVA Therapeutics (NASDAQ:LVTX) Sees Large Growth in Short Interest

LAVA Therapeutics (NASDAQ:LVTX) saw a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 19,100 shares, a growth of 695.8% from the October 15th total of 2,400 shares. Approximately 0.1% of the company’s stock are short sold. Based on an average daily volume of 49,600 shares, the short-interest ratio is currently 0.4 days.

Analysts Set New Price Targets

Separately, JMP Securities restated a “market outperform” rating and issued a $6.00 target price on shares of LAVA Therapeutics in a research report on Wednesday, August 21st.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in LAVA Therapeutics stock. XTX Topco Ltd acquired a new stake in LAVA Therapeutics (NASDAQ:LVTX) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 30,807 shares of the company’s stock, valued at approximately $55,000. XTX Topco Ltd owned 0.12% of LAVA Therapeutics at the end of the most recent quarter.

LAVA Therapeutics Price Performance

Shares of NASDAQ:LVTX traded down $0.09 during trading on Tuesday, reaching $1.76. The company had a trading volume of 22,775 shares, compared to its average volume of 568,679. The firm’s fifty day moving average is $1.73 and its 200 day moving average is $2.03. The firm has a market capitalization of $44.62 million, a PE ratio of -2.03 and a beta of 0.49. LAVA Therapeutics has a twelve month low of $1.35 and a twelve month high of $6.47. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.39 and a current ratio of 6.39.

LAVA Therapeutics (NASDAQ:LVTX) last posted its quarterly earnings data on Tuesday, August 20th. The company reported ($0.31) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.05. LAVA Therapeutics had a negative net margin of 228.02% and a negative return on equity of 48.53%. On average, equities analysts forecast that LAVA Therapeutics will post -1.28 EPS for the current year.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.